1. Home
  2. TRTX vs RIGL Comparison

TRTX vs RIGL Comparison

Compare TRTX & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TPG RE Finance Trust Inc.

TRTX

TPG RE Finance Trust Inc.

HOLD

Current Price

$8.45

Market Cap

720.8M

Sector

Real Estate

ML Signal

HOLD

Logo Rigel Pharmaceuticals Inc.

RIGL

Rigel Pharmaceuticals Inc.

HOLD

Current Price

$36.43

Market Cap

683.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TRTX
RIGL
Founded
2014
1996
Country
US
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
720.8M
683.2M
IPO Year
N/A
2000

Fundamental Metrics

Financial Performance
Metric
TRTX
RIGL
Price
$8.45
$36.43
Analyst Decision
Buy
Strong Buy
Analyst Count
3
5
Target Price
$10.75
$43.20
AVG Volume (30 Days)
760.8K
250.8K
Earning Date
01-01-0001
04-01-2026
Dividend Yield
10.90%
N/A
EPS Growth
N/A
807.14
EPS
N/A
5.38
Revenue
N/A
$179,278,000.00
Revenue This Year
N/A
$66.81
Revenue Next Year
$0.86
N/A
P/E Ratio
$14.82
$6.64
Revenue Growth
N/A
53.38
52 Week Low
$6.47
$15.50
52 Week High
$9.85
$52.24

Technical Indicators

Market Signals
Indicator
TRTX
RIGL
Relative Strength Index (RSI) 31.60 49.76
Support Level $8.70 $33.23
Resistance Level $9.09 $34.99
Average True Range (ATR) 0.26 1.45
MACD -0.07 0.39
Stochastic Oscillator 13.82 95.56

Price Performance

Historical Comparison
TRTX
RIGL

About TRTX TPG RE Finance Trust Inc.

TPG RE Finance Trust Inc is a commercial real estate finance company. It originates, acquires, and manages commercial mortgage loans and other commercial real estate-related debt instruments consisting of first mortgage loans and senior participation interests in first mortgage loans secured by institutional-quality properties in primary and select secondary markets in the United States. The company's objective is to provide attractive risk-adjusted returns to its stockholders over time through cash distributions and capital appreciation. It focuses on directly originating and selectively acquiring floating rate first mortgage loans that are secured by high quality commercial real estate properties undergoing some form of transition and value creation.

About RIGL Rigel Pharmaceuticals Inc.

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

Share on Social Networks: